Table 2.
Treatment-emergent adverse events reported by ≥5% of patientsa
| n (%) | |
| Duloxetine, 60 mg QD (N = 533) | |
| Nausea | 191 (35.8) |
| Headache | 108 (20.3) |
| Dry mouth | 96 (18.0) |
| Somnolence | 72 (13.5) |
| Insomnia | 56 (10.5) |
| Dizziness | 54 (10.1) |
| Diarrhea | 53 (9.9) |
| Constipation | 42 (7.9) |
| Increased sweating | 37 (6.9) |
| Anxiety | 33 (6.2) |
| Decreased appetite | 33 (6.2) |
| Tremor | 32 (6.0) |
| Fatigue | 31 (5.8) |
| Vomiting | 28 (5.3) |
a Incidence is defined as the percentage of subjects reporting a first occurrence or worsening of the event during the acute phase of the study.